

October 2018



SAUNDRA PELLETIER, CEO

NASDAQ: EVFM

# Disclaimer


This presentation contains forward looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws. In some cases, you can identify forward looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “strategy,” “designed,” “suggest,” “currently,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward looking statements of this presentation are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation risks and uncertainties relating to: the outcome or success of Evofem’s clinical trials; Evofem’s ability to obtain the necessary regulatory approvals for its product candidates, including approval from the U.S. Food and Drug Administration for the use of Amphora® for prevention of pregnancy, and the timing of such approvals; the rate and degree of market acceptance of Amphora®; Evofem’s ability to successfully commercialize Amphora® and its ability to develop sales and marketing capabilities; Evofem’s ability to maintain and protect its intellectual property; Evofem’s ability to raise additional capital when needed and to rely on existing cash reserves to fund its current development plans and operations; Evofem’s reliance on third party providers, such as third party manufacturers and clinical research organizations; the absence of any adverse events or side effects relating to the use of Amphora®; Evofem’s ability to retain members of its management and other key personnel; and other risk factors detailed in Evofem’s filings from time to time with the U.S. Securities and Exchange Commission. The forward looking statements in this presentation represent Evofem’s views only as of the date of this presentation, October 1, 2018, and Evofem undertakes no obligation to update or review any forward looking statement, whether as a result of new information, future developments or otherwise, except as required by law.

# Company Overview

- Clinical-stage biopharmaceutical company located in San Diego, CA
- Committed to discovery, development and commercialization of innovative women's health pharmaceuticals
- R&D focused on the first *Multipurpose Vaginal pH Regulator* (MVP-R): a multiple indication franchise
- Lead product candidate Amphora® is a non-hormonal, on-demand, woman-controlled vaginal gel
  - Phase 3 confirmatory birth control study (top-line data read out late 2018)
  - Phase 2b study for the prevention of chlamydia (actively enrolling)
- Accomplished executive leadership team with more than 80 years of combined experience in women's healthcare

# 16.5M Women Say They Do Not Want To Get Pregnant But Are Doing Nothing To Prevent It From Happening

*Amphora Targets U.S. Women 15-44 Years Old  
(in Millions)<sup>1</sup>*



***Sexually Active Women Not Using Birth Control Have  
an 85% Risk of Pregnancy Within 12 Months<sup>2</sup>***


Source:

1. Derived from NCHS Data Brief No. 173\_December 2014 and the 2016 US Census Bureau data.

2 Trussell J, Nelson AL, Cates W, Kowal D, Policar M. Contraceptive Technology: Twentieth Revised Edition. New York, NY. Ardent Media, 2011.

# Amphora Addresses Unmet Needs by Offering Innovative Benefits

amphora<sup>®</sup>




\*Body Mass Index

<sup>^</sup>Patent pending

# Multipurpose Vaginal pH Regulator (MPV-R) Mechanism of Action

- Active compounds: L-lactic acid, citric acid, and potassium bitartrate
- Maintains acidic vaginal environment even after the introduction of semen into the vagina, inhibiting motility, and preventing the survival of spermatozoa
  - Acidic environments are inhospitable to microbes such as chlamydia
- Highly bioadhesive, forming a layer over vaginal and cervical surfaces



# Market Research Supports Significant Opportunity for Amphora

*~2/3 of women cited side effects as the reason they discontinued hormones<sup>1</sup>*

Amphora as their Primary Method of birth control  
(30% of respondents)


- Desire non-hormonal birth control as driver to change

Amphora as their Supplemental Method of birth control  
(28% of respondents)

- Highly engaged in their own healthcare
- Need to protect against unintended pregnancy

Currently Satisfied with their birth control method  
(42% of respondents)

- Satisfied with current prescription contraceptive



Source:

1. Daniels K, Mosher WD, Jones J. Contraceptive methods women have ever used: United States, 1982–2010. National health statistics reports; no 62. Hyattsville, MD: National Center for Health Statistics. 2013.


# Amphora Go to Market Strategy: Market Access

## *Market Access Account and Distribution Strategies will be Deployed with Key Influential National and Regional Accounts for Ease of Access and Affordability*

- The Affordable Care Act (ACA) covering preventive healthcare requires that women have access to a full range of contraceptive options and that they receive them with no out-of-pocket expenses
  - Following advice from insurance company medical directors and pharmacy benefit managers covering 70% of U.S. lives, Amphora is anticipated to qualify as one of the covered contraceptive options under the ACA mandate
- Market research suggests that payers like the idea of a new birth control option due to the:
  - a) High incidence of unintended pregnancies;
  - b) High costs associated with these unintended pregnancies and;
  - c) The unmet needs in the birth control category (i.e., the lack of hormone free options)<sup>1</sup>

# Amphora Go To Market Strategy: Sales & Marketing

**85 Sales Representatives Cover ~96% of Top Prescribers of Contraceptive Prescriptions<sup>1</sup>**



Colored areas denote individual territories based on Quintiles analysis

98% of the most important prescribers in the birth control category come from the OB/GYN specialty<sup>2</sup>

- Healthcare provider attitudinal segmentation will optimize targeting and messaging frequency
- Initiation of direct to consumer marketing will commence 6-9 months post launch to make women aware of the non-hormonal birth control option, Amphora



Sources:


1. Quintiles – March 18, 2016: Evofem\_Target\_Universe\_PCP+OBGYN\_10USC\_4Feb2016.xlsx
2. IMS Nov'15 Prescription Data

**EVOFEM**  
BIO SCIENCES™

# AMP-002: Confirmatory Phase 3 Birth Control Trial

- Single-arm, open label trial in ~1,400 women age 18-35 at 112 U.S. sites
- Enrollment completed in February 2018
- 5 gram dose of Amphora administered immediately before or up to one hour before intercourse
- Primary endpoint: prevention of pregnancy over seven cycles
- Exploratory endpoint: sexual satisfaction

## *Top-line Results Expected Late 2018*



# MVP-R Label Expansion Opportunity: Amphora for the Prevention of Chlamydia

- 1.7M new cases of chlamydia in 2017 in U.S.<sup>1</sup>
- Phase 2b trial – enrollment ongoing
  - Double-blinded, placebo-controlled efficacy trial at ~50 U.S. sites
  - 844 women, 18-45 years old, with chlamydia infection in the past four months
  - Four-month interventional period and one-month follow-up
  - Primary endpoint: prevention of *Chlamydia trachomatis* in women
- Fast Track designation for prevention of urogenital chlamydia in women has been granted by FDA

***The additional potential indication for the prevention of chlamydia should make Amphora an even more appealing birth control option***

Source:

1. CDC preliminary data in five-year trends in sexually transmitted diseases 2017

# MVP-R Second Product Candidate: Prevention of Recurrent Bacterial Vaginosis (BV)

- BV is caused by an imbalance of a woman's vaginal bacteria
  - Symptoms: unpleasant odor and abnormal vaginal discharge
  - Current standard of care: prolonged course of antibiotic treatment
    - No FDA approved drug for the prevention of BV
- BV has up to a 58% recurrence rate<sup>1</sup>
- Phase 1 dose-finding study completed
  - pH levels maintained for seven days
- Designated by FDA as Qualified Infectious Disease Product (QIDP)<sup>2</sup>
  - Eligible for FDA's Fast Track
  - Adds five years of market exclusivity for BV indication

Sources:

1. Bradshaw CS et al., High Recurrence Rates of Bacterial Vaginosis over the Course of 12 Months after Oral Metronidazole Therapy and Factors Associated with Recurrence. *The Journal of Infectious Diseases* 193:1478-86 (2006).
2. While we have received a QIDP designation, we may be required to reapply should we alter the formulation of this product candidate.

# Proven Leadership in Women's Healthcare



**Sandra Pelletier**  
Chief Executive Officer



**Jay File**  
Chief Financial Officer



**Kelly Culwell, M.D.**  
Chief Medical Officer



**Russell Barrans**  
Chief Commercial Officer

**Over 80 Years**  
of Established Commercial  
and Clinical Experience in Women's Healthcare

# Evofem Biosciences Highlights

<b>Innovation</b>	<p>Multipurpose Vaginal pH Regulator multiple indication franchise</p> <ul style="list-style-type: none"> <li>• Amphora commercial launch anticipated in January 2020 (for prevention of pregnancy)</li> </ul>
<b>Expertise</b>	World class executive leadership team
<b>Unmet Need</b>	16.5M women are not using any birth control while not wanting to become pregnant, indicating a significant market opportunity
<b>Analytics</b>	Segmentation allows for precision marketing and sales force targeting
<b>Measurement</b>	<p>Near term catalysts:</p> <ul style="list-style-type: none"> <li>• Phase 3 confirmatory study top-line results expected late 2018</li> <li>• Expected NDA submission Q2 2019</li> </ul>
<b>Pipeline</b>	<p>Additional MVP-R development opportunities:</p> <ul style="list-style-type: none"> <li>• Prevention of chlamydia (label expansion opportunity for Amphora)</li> <li>• Prevention of recurrent bacterial vaginosis (second MVP-R product candidate)</li> </ul>
<b>Exclusivity</b>	IP through 2033*

\*Patent pending



EVOFEM

---

B I O S C I E N C E S™